Anticholinergic burden in older women: not seeing the wood for the trees? by Parkinson, L. et al.
Research

















MB BS(Hons), FRACP, PhD7,8







MB BS, FRACGP, PhD2
Abstract
Objectives: To identify medicines contributing to and describe predictors 
of anticholinergic burden among community-dwelling older Australian 
women.
Design, setting and participants: Retrospective longitudinal analysis of 
data from the Australian Longitudinal Study on Women’s Health linked to 
Pharmaceutical Benefits Scheme medicines data from 1 January 2008 to 
30 December 2010; for 3694 women born in 1921–1926.
Main outcome measures: Anticholinergic burden calculated from 
Anticholinergic Drug Scale (ADS) scores derived from ADS levels (0 to 3) 
for all medicines used by each woman, summed over each 6-month period 
(semester), medicines commonly used by women with high semester ADS 
scores (defined as 75th percentile of scores).
Results: 1126 women (59.9%) used at least one medicine with 
anticholinergic properties. The median ADS score was 4 or 5 across all 
semesters. Most anticholinergic medicines used by women who had a high 
anticholinergic burden (ADS score,  9) had a low anticholinergic potency 
(ADS level 1). Increasing age, cardiovascular disease, and number of other 
medicines used were predictive of a higher anticholinergic burden.
Conclusions: A high anticholinergic medicines burden in this group was 
driven by the use of multiple medicines with lower anticholinergic potency 
rather than the use of medicines with higher potency. This is a novel and 
important finding for clinical practice as doctors would readily identify 
the risk of a high anticholinergic burden for patients using high potency 
medicines, but may be less likely to identify this risk for users of multiple 
medicines with low anticholinergic potency.
Anticholinergic burden in older women: not seeing 
the wood for the trees?
O
lder people are particularly 
vulnerable to adverse medi-
cines-related events. Reasons 
for this include the physiological 
changes of ageing, the chronic and 
comorbid conditions they often have, 
the types of medicines they are com-
monly prescribed, and the frequency 
with which they use multiple medi-
cines.1,2 Adverse effects related to 
medicine use are a significant health 
problem in this growing population 
group.3 Many medicines used by 
older people have anticholinergic 
effects (effects through one of the 
body’s principal neurotransmitter 
systems).4 The anticholinergic effect 
of an individual medicine may be 
small, but the anticholinergic effects 
of multiple medicines may be addi-
tive, constituting “anticholinergic 
burden”.1,4,5
The degree of anticholinergic effect 
varies greatly between drugs and 
drug classes.6 Drug classes with 
anticholinergic effects that are com-
monly used by older people include 
gastrointestinal antispasmodics, 
medicines used for urge inconti-
nence, antipsychotics, and tricyclic 
antidepressants.4 The anticholinergic 
effect may be intrinsic to the thera-
peutic effect of the medicine or an 
unintended side effect.4
Relatively minor anticholinergic 
adverse effects that are readily 
apparent include dry mouth, con-
stipation and blurred vision.4 More 
serious effects, such as confusion and 
impaired cognition, have also been 
consistently associated with anticho-
linergic medicines.7-10 Anticholinergic 
burden can also affect functional sta-
tus in older people, generally related 
to instrumental activities of daily liv-
ing (skills necessary for individuals 
to live independently);1,7 balance, gait 
and mobility;5 and is associated with 
falls and frailty.9,11
An Australian study found that 21% 
of community-dwelling men aged 70 
years or older were taking medicines 
with definite anticholinergic effects.1 
Although women outnumber men in 
the older population,3 research into 
anticholinergic medicine use has 
focused predominantly on mixed 
sex and male samples.1,8,11 However, 
United States studies have shown 
that 15% of women aged 75 years 
and older12 and 11% of women aged 
50–79 years13 used anticholinergic 
medicines. 
Women may have a particular pro-
pensity to be prescribed highly 
anticholinergic medicines for condi-
tions such as urinary incontinence 
and chronic neuropathic pain, and 
they use an increasing number of 
medicines as they age. The cumula-
tive anticholinergic effects of these 
medicines can increase the risk of 
serious functional impairment, nega-
tively affecting independence in older 
age. In this study we aimed, for the 
period 2008 to 2010, to: 
• describe the anticholinergic 
medicine burden among a com-
munity-based sample of older 
women from the Australian 
Longitudinal Study on Women’s 
Health (ALSWH); 
• identify medicines and combina-
tions of medicines that make the 
greatest contribution to anticho-
linergic burden; and
• describe the predictors of high 
anticholinergic medicine burden.
Methods
In this retrospective observational 
longitudinal study, we analysed sur-
vey data from the ALSWH, linked 
to Pharmaceutical Benefits Scheme 
(PBS) data. Ethics approval for data 
collection, linkage and analyses was 
obtained through the University of 
Queensland, University of Newcastle 
and Australian Department of Health 
and Ageing.
Sample
The sample included women from 
the ALSWH “older” cohort (born 
in 1921–1926), who had completed 
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linkage, had concessional status for 
the PBS and had made at least one 
medicine claim from 1 January 2008 
to 30 December 2010. 
Data sources
ALSWH survey data: The ALSWH 
is a national study that began in 
1996 with a random sample of more 
than 40 000 women in three birth 
cohorts. Here, we focus on those in 
the older cohort, born in 1921–1926, 
who completed Survey 1 in 1996. 
Since 1998, follow-up surveys have 
been completed every 3 years. The 
older cohort were aged 70–75 years 
at Survey 1 (12 432 women) and 82–87 
years at Survey 5 in 2008 (5560 wo-
men). Deaths are ascertained using 
the National Death Index. 
Compared with the general popula-
tion, women in the cohort have had 
a small relative survival advantage, 
mainly due to baseline demographic 
and health behaviour differences. 
Compared with national data, under-
representation of women born in non-
English-speaking countries and those 
who were underweight has increased 
slightly over the course of the study.14 
Such small biases are unlikely to 
affect measures of association.
The surveys covered a range of 
health, social, psychological and 
demographic variables. Detailed 
methods and surveys are available 
from the ALSWH website (http://
www.alswh.org.au).
Medicines data: These were records 
of subsidised prescriptions under the 
PBS and Repatriation PBS (RPBS) pro-
vided by Medicare Australia, for the 
calendar years 2008 through 2010. 
These records provide reliable data 
about dates of services and medicine 
types. The ALSWH study uses deter-
ministic linkage between survey and 
individual PBS data, using personal 
identifier numbers held by Medicare.
PBS data include only PBS-listed 
prescription medicines that attract a 
government subsidy, so they do not 
include medicines provided in hos-
pital or purchased over-the-counter 
(OTC). Although OTC medicines with 
anticholinergic activity are not cap-
tured by the PBS, we did not expect a 
significant impact on our results, as at 
ALSWH Survey 4 (2005), less than 5% 
of women in the older cohort reported 
OTC medicine use.15 Medicines data 
for those with concessional status are 
captured consistently by PBS, as all 
PBS medicines cost more than the 
concessional status threshold and 
will always attract a government 
subsidy.
Statistical analyses
PBS data were coded to conform to 
Anatomical Therapeutic Chemical 
Codes.16
Anticholinergic medicines were 
identified and their potency rated 
using the Anticholinergic Drug Scale 
(ADS),6 as follows. 
Level 1: potentially anticholinergic as 
evidenced by receptor binding stud-
ies (for example, frusemide, digoxin, 
or captopril).
Level 2: anticholinergic adverse 
events sometimes noted, usually at 
excessive doses (for example, car-
bamazepine, cyproheptadine, or 
disopyramide).
Level 3: markedly anticholinergic 
(for example, amitriptyline, brom-
pheniramine, or oxybutynin).6 
The ADS provides a measure of 
anticholinergic burden assessed 
from serum anticholinergic activ-
ity for individual medicines;6 and 
has recently been shown to predict 
adverse medicines-related events.17
The characteristics of women who 
used at least one anticholinergic med-
icine at any time from 2008 through 
2010 were compared with those who 
did not use any, using χ  2 tests for cate-
gorical variables and two-sided t tests 
for continuous variables.
The ADS potency ratings (level 1, 2 
or 3) of all anticholinergic medicines 
claims for each woman were summed 
to give individual 6-month anticho-
linergic burden (ADS) scores (semes-
ters were January to June and July to 
December each year), for 2008 to 2010. 
We did not consider medicine doses 
in calculating ADS scores, as it has 
been shown that including the dose 
does not improve ADS correlation 
with serum anticholinergic activity.6
ADS scores were tabulated and 
graphed. High ADS scores were those 
in the 75th percentile of all scores, 
and above. Anticholinergic medicines 
associated with high 6-month ADS 
scores were identified.
The predictors of high 6-month ADS 
scores for women using anticholiner-
gic medicines were analysed using 
stepwise backwards generalised esti-
mating equations (GEE), with the sig-
nificance level set at P < 0.05. Women 
who made no claims for anticho-
linergic medicines were excluded 
as they are likely to be a different 
population to those who receive at 
least one anticholinergic medicine, 
and including them would errone-
ously intensify differences between 
groups. Sociodemographic covari-
ates considered in the model were: 
age, area of residence (rural/urban), 
education level (secondary or above/
below secondary), living arrange-
ments (alone/with others), marital 
status (partnered/not). Lifestyle 
covariates were: smoking status (cur-
rent/not), alcohol use (yes/no), body 
mass index (mean).18 Health covari-
ates included: conditions (yes/no for 
mental health problems [depression, 
anxiety, or nervous disorder], cardio-
vascular disease [heart attack, other 
heart problems, or stroke], diabetes, 
arthritis, asthma, cancer [excluding 
skin cancer], and osteoporosis), total 
number of other (not anticholinergic) 
medicines, quality of life (measured 
by the 36-item short form health sur-
vey [SF-36]).19
All statistical analyses were per-
formed in Stata/IC, version 11 
(StataCorp). Data file construction 




There were 5560 women born in 1921–
1926 who returned ALSWH Survey 5; 
3694 of these (66.4%) consented to PBS 
linkage (for 2008, 2009, and 2010). Of 
those 3694, 1883 (51.0%) had at least 
one PBS claim from 2008 to 2010, and 
had concessional PBS status. Of these 
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anticholinergic medicine claim from 
2008 to 2010. 
Appendix 1 shows that, compared 
with women who had no anticho-
linergic medicines claims, the group 
with anticholinergic medicines 
claims had: a lower proportion of 
women with a secondary education 
or higher (P < 0.05); a higher mean 
BMI (P < 0.05); a higher proportion 
with cancer (P < 0.05), a mental health 
problem (P < 0.001), asthma (P < 0.001), 
cardiovascular disease (P < 0.001), and 
arthritis (P < 0.001); higher multimor-
bidity (P < 0.001). They also performed 
less well on all SF-36 scales (P < 0.001)
Use of anticholinergic 
medicines
Fifty different anticholinergic medi-
cines were used by this group (21 at 
ADS level 3, four at ADS level 2 and 
25 at ADS level 1). The proportion 
of women who used anticholinergic 
medicines increased over the 3 years, 
from 783 (42.5%) in 2008 to 823 (46.9%) 
in 2010 (Box 1). Just over a third of 
women using anticholinergic medi-
cines (34.3%) used these in all six 
semesters, 25.7% used them in only 
one, 14.7% used them in two, 10.8% 
in three, 7.9% in four, and 6.8% in five 
semesters. The median number of 
claims for anticholinergic medicines 
per woman was four (interquartile 
range [IQR], 2–7) in all semesters. 
Most anticholinergic medicines used 
were at ADS level 1.
Anticholinergic burden (ADS 
score)
ADS scores were relatively stable 
across all semesters over the 3 years, 
as shown in Box 2. Median ADS 
scores were 4 or 5 in all semesters. A 
high ADS score for a semester was 
defined as  9 (75th percentile of 
scores).
Main contributors to 
anticholinergic burden
Most anticholinergic medicines used 
by women with high ADS scores 
were at ADS level 1. Given the di-
versity of ADS medicines used, we 
identified no common combinations 
of medicines contributing to high 
ADS scores. The 10 most commonly 
used anticholinergic medicines in 
women with high ADS scores were 
very similar across the six semesters: 
amitriptyline (level 3), digoxin (level 
1), doxepin (level 3), frusemide (level 
1), isosorbide (level 1), nifedipine 
(level 1), oxycodone (level 1), pred-
nisolone (level 1), and warfarin (level 
1) were present in each semester, 
with fentanyl (level 1) in four and 
dothiepin (level 3) in two semesters 
(Appendix 2).
Characteristics of older women 
with a high anticholinergic 
burden
The final parsimonious GEE model 
showed that increasing age, self-
report of cardiovascular disease 
(heart attack, other heart problems, 
and stroke) and number of other (not 
anticholinergic) medicines were pre-
dictive of a higher anticholinergic 
burden for women using anticho-
linergic medicines (Box 3).
1  Claims for anticholinergic medicines (AM) by Australian women aged 82–89 years, annually and 6-monthly, 2008 through 2010
Year




AM claims by ADS level* Number of AM claims
Level 1 Level 2 Level 3 Min Q1 Median Q3 Max
2008
Annual 1844 783 (42.5%) 687 16 174 1 2 6 12 56
Jan–Jun 1822 633 (34.7%) 555 13 130 1 2 4 7 33
Jul–Dec 1808 681 (37.7%) 593 13 147 1 2 4 7 27
2009
Annual 1812 796 (43.9%) 694 16 187 1 2 6 12 44
Jan–Jun 1786 654 (36.6%) 566 11 142 1 2 4 7 37
Jul–Dec 1768 683 (38.6%) 592 13 149 1 2 4 7 27
2010
Annual 1755 823 (46.9%) 733 21 169 1 2 6 13 50
Jan–Jun 1734 677 (39.0%) 594 17 135 1 2 4 7 24
Jul–Dec 1702 706 (41.5%) 628 13 137 1 2 4 7 26
ADS = anticholinergic drug scale. Min = minimum. Max = maximum. Q1 = 25th percentile. Q3 = 75th percentile. 
* Level 1, 2 and 3 AM claims are not mutually exclusive.  
2  Anticholinergic drug scale scores for 1126 Australian women aged 82–89 years who used 




Anticholinergic drug scale scores
Minimum Q1 Median Q3 Maximum
2008 Jan–Jun 633 1 2 5 9 33
Jul–Dec 681 1 2 5 9 30
2009 Jan–Jun 654 1 2 4 8 37
Jul–Dec 683 1 2 5 8 39
2010 Jan–Jun 677 1 2 5 8 39
Jul–Dec 706 1 2 5 9 33
Q1 = 25th percentile. Q3 = 75th percentile.  
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Discussion
This study showed that a high pro-
portion of older women have a sub-
stantial anticholinergic burden, and 
that this high burden is driven by the 
use of multiple medicines with lower 
anticholinergic potency rather than 
use of medicines with higher anticho-
linergic potency. Our study is one of 
the few in Australia and internation-
ally that evaluate anticholinergic bur-
den in older women. It is also unique 
in that it examines anticholinergic 
burden longitudinally, using continu-
ous and reliable data on medicines 
from the PBS.
While there are many methods for 
measuring anticholinergic burden,4,20 
we used the ADS, which provides 
a measure of anticholinergic bur-
den that correlates well with serum 
anticholinergic activity measures.6 
A US clinic-based study of women 
aged 75 years and older, using a 
similar measure of anticholinergic 
burden, found that mean burden 
increased significantly in the 10 years 
of their study; however, only 15% of 
participants were using anticho-
linergic medicines within the last 
month at follow-up.12 Another US 
study using data from the Women’s 
Health Initiative found that 11% 
of women aged 50–79 years were 
using an anticholinergic medicine 
at baseline.13 Although we found 
that median anticholinergic burden 
did not increase over time, 35% of 
our community sample were using 
anticholinergic medicines during the 
6-month baseline semester, and this 
proportion increased significantly 
over time. Over a third of women 
using anticholinergic medicines used 
these in all semesters, suggesting con-
tinuous use.
Total avoidance of medicines with 
anticholinergic properties for older 
people is neither practicable nor 
necessarily desirable.21 Multiple 
medicines use is not only common 
among older adults, but is important 
for ameliorating symptoms, improv-
ing quality of life, and sometimes for 
curing disease.21 Individual prescrib-
ing decisions about medicines with 
anticholinergic activity, as with all 
medicines, will always involve assess-
ing the potential benefits and harms22 
and, in past research, we showed that 
anticholinergic burden is an area 
where assessing the risk is problem-
atic.23 In interviews with Australian 
general practitioners we found that 
they have limited understanding of 
the concept of anticholinergic burden 
and the range of medicines that con-
tribute to it, despite otherwise hav-
ing a sophisticated understanding 
of potential medicine adverse events 
and managing this risk.
The predictors of a high anticho-
linergic burden were generally not 
unexpected for the group we studied. 
One of our aims in this analysis was 
to identify characteristics of older 
people that might alert doctors to a 
particular risk of higher anticholin-
ergic medicine burden. While unre-
markable predictors may not be very 
informative in clinical practice, our 
study does emphasise that identify-
ing a higher anticholinergic medicine 
burden is complex, and there appear 
to be no simple flags to help doctors 
identify the risk.
Our study has some potential limi-
tations. While the PBS provides 
comprehensive data, as outlined 
in the methods, it does not include 
all medicines (eg, OTC medicines). 
Although we expect this would not 
have significantly affected our find-
ings, this limitation may mean that 
our calculation of burden is conserva-
tive. Also, as medicines costing less 
than the patient “copayment” will not 
be captured in the PBS,24 we restricted 
our analyses to women with “conces-
sional” status, as is common practice.2 
As the vast majority of older women 
have concessional status, the effect on 
the generalisability of our findings to 
this group should be limited. 
Conclusions
It is a novel and important finding 
for clinical practice that high an-
ticholinergic medicines burden in 
this group was driven by the use 
of multiple medicines with lower 
anticholinergic potency rather than 
by those with higher anticholiner-
gic potency. While we might expect 
that doctors would readily identify 
anticholinergic burden as a risk in 
patients using medicines with high 
anticholinergic potency, they may 
be less likely to perceive a risk for 
patients using multiple medicines 
with lower anticholinergic potency. 
Developing a means of calculating 
the anticholinergic burden of drug 
regimens (and of the contributions of 
individual drugs) and incorporating 
this into GPs’ prescribing software 
would be appropriate. Our find-
ings provide important evidence to 
underpin prescribing practice and 
policy aimed at reducing disability 
and adverse medicine events among 
older women, and may apply to all 
older people.
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3  Multivariate generalised estimating equation regression of explanatory variables (final 
model) for anticholinergic medicine users with a high anticholinergic burden (ADS score 
 9) compared with those with lower anticholinergic burden (ADS score < 9)
Variable Odds ratio (95% CI) SE P
Age 1.05 (1.01–1.08) 0.02 0.006*
Education ( secondary) 0.85 (0.72–1.00) 0.07 0.056
Alcohol use 0.86 (0.73–1.02) 0.07 0.089
Cardiovascular disease 1.25 (1.05–1.47) 0.11 0.010*
SF-36 pain index 1.00 (1.00–1.01) 0.00 0.047
SF-36 general health perception 0.99 (0.99–1.00) 0.00 0.005*
Number of non-anticholinergic medicines 1.05 (1.04–1.06) 0.01 0.000*
ADS = anticholinergic drug scale. SF-36 = 36-item short form health survey.
* Significant difference (P < 0.05).  
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